section name header

Pronunciation

KROE-moe-lin

Classifications

Therapeutic Classification: antiasthmatics, allergy, cold and cough remedies

Pharmacologic Classification: mast cell stabilizers

Indications

REMS


Action

  • Prevents the release of histamine and slow-reacting substance of anaphylaxis (SRS-A) from sensitized mast cells.
Therapeutic effects:
  • Decreased frequency and intensity of asthmatic episodes or allergic reactions.

Pharmacokinetics

Absorption: Oral: 0.5—2 %; Inhalation: Poorly absorbed systemically (total bioavailability is 8%); action is local. Small amounts may reach systemic circulation after inhalation.

Distribution: Because only small amounts are absorbed, distribution is not known.

Metabolism/Excretion: Small amounts absorbed are excreted unchanged in bile and urine.

Half-Life: 80–90 min.

Time/Action Profile

ROUTEONSETPEAKDURATION
Cromolyn-inhalation1–2 wk2–4 wkunknown
Cromolyn-nasal1–2 wk2–4 wkunknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Gastrocrom, NasalCrom

Canadian Brand Names

Apo-Cromolyn

Pot. Nursing Diagnoses

Code

NDC Code